According to the research report, the global pharmaceutical contract sales outsourcing (CSO) market size is expected to touch USD 21.24 Billion by 2032, from USD 9.23 Billion in 2022, growing with a significant CAGR of 8.69% from 2023 to 2032.
![Pharmaceutical Contract Sales Outsourcing [CSO] Market Size 2023 To 2032](https://www.precedenceresearch.com/insightimg/pharmaceutical-contract-sales-outsourcing-market-size.jpg "Pharmaceutical Contract Sales Outsourcing [CSO] Market Size 2023 To 2032")
The pharmaceutical contract sales outsourcing (CSO) report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global pharmaceutical contract sales outsourcing (CSO) in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global pharmaceutical contract sales outsourcing (CSO) market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global pharmaceutical contract sales outsourcing (CSO) during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2766
Report Scope of the Pharmaceutical Contract Sales Outsourcing (CSO) Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 10.03 Billion |
| Market Size by 2032 | USD 21.24 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.69% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Service and By Therapeutic Area |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global pharmaceutical contract sales outsourcing (CSO) market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global pharmaceutical contract sales outsourcing (CSO) market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- IQVIA Inc.
- Syneos Health Inc.
- Parexel International Corporation
- Pharmaceutical Product Development (PPD) LLC
- inVentiv Health Inc. (part of Syneos Health)
- ICON plc
- Publicis Touchpoint Solutions, Inc.
- PRA Health Sciences, Inc.
- The Medical Affairs Company (TMAC)
- Ashfield Healthcare Communications Group (part of UDG Healthcare plc)
Market Segmentation
By Service
- Personal Promotion
- Non-personal Promotion
- Others
By Therapeutic Area
- Cardiovascular Disorders
- Oncology
- Metabolic Disorders
- Neurology
- Orthopedic Diseases
- Infectious Diseases
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global pharmaceutical contract sales outsourcing (CSO) report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pharmaceutical contract sales outsourcing (CSO) market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical Contract Sales Outsourcing (CSO) Market
5.1. COVID-19 Landscape: Pharmaceutical Contract Sales Outsourcing (CSO) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Service
8.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service, 2023-2032
8.1.1. Personal Promotion
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Non-personal Promotion
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Therapeutic Area
9.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area, 2023-2032
9.1.1. Cardiovascular Disorders
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Metabolic Disorders
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Orthopedic Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Infectious Diseases
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2020-2032)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2020-2032)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2020-2032)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
Chapter 11. Company Profiles
11.1. IQVIA Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Syneos Health Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Parexel International Corporation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pharmaceutical Product Development (PPD) LLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. inVentiv Health Inc. (part of Syneos Health)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ICON plc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Publicis Touchpoint Solutions, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PRA Health Sciences, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. The Medical Affairs Company (TMAC)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ashfield Healthcare Communications Group (part of UDG Healthcare plc)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments